Importance Multiple myeloma is a hematologic malignancy characterized by presence of
abnormal clonal plasma cells in the bone marrow, with potential for uncontrolled growth …

Abstract Gain of chromosome 1q (+ 1q) is one of the most common recurrent cytogenetic
abnormalities in multiple myeloma (MM), occurring in approximately 40% of newly …

PURPOSE Patients with newly diagnosed multiple myeloma (NDMM) show heterogeneous
outcomes, and approximately 60% of them are at intermediate-risk according to the Revised …

Despite substantial advances in anti-myeloma treatments, early recurrence and death
remain an issue in certain subpopulations. Cytogenetic abnormalities (CAs) are the most …

Background The introduction of immunomodulatory agents, proteasome inhibitors, and
autologous haematopoietic stem-cell transplantation has improved outcomes for patients …

PURPOSE The GMMG-CONCEPT trial investigated isatuximab, carfilzomib, lenalidomide,
and dexamethasone (Isa-KRd) in transplant-eligible (TE) and transplant-noneligible (TNE) …

Venetoclax (Ven) is a selective small‐molecule inhibitor of BCL‐2 that exhibits antitumoral
activity against MM cells with t (11; 14) translocation. We evaluated the safety and efficacy of …

Some genetic abnormalities of multiple myeloma (MM) detected more than two decades ago
remain major prognostic factors. In recent years, the introduction of cutting-edge genomic …

PURPOSE High levels of circulating tumor plasma cells (CTC-high) in patients with multiple
myeloma are a marker of aggressive disease. We aimed to confirm the prognostic impact …

Simple Summary Multiple myeloma (MM), a plasma cell neoplasm, is an incurable
hematological malignancy. Gain/amplification of chromosome arm 1q21 (1q21+) is the most …